Trial results of the Pfizer’s new Covid wonderpill indicates that it can cut hospitalisations and death by 89%.
The pharmaceutical company will submit the interim results to the US Food and Drug Administration for use.
New data published by Pfizer seems to outperform Merck & Co Inc’s pill, Molnupiravir which showed that it could halve people dying of being admitted to hospital for the virus.
Molnupiravir Covid pill will be rolled out across the UK alongside other vaccines.
Dr Mikael Dolsten, Pfizer’s chief scientific officer said, “All of us at Pfizer are incredibly proud of our scientists, who designed and developed this molecule, working with the utmost urgency to help lessen the impact of this devastating disease on patients and their communities.
“We’re thankful to all of the patients, investigators, and sites around the world who participated in this clinical trial, all with the common goal of bringing forth a breakthrough oral therapy to help combat Covid-19.”
He added, “We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death.”
Albert Bourla, Pfizer CEO, said, “These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of ten hospitalisations.”